AI models for protein design (Chai Bio) and genomic modeling (Arc Institute's Evo 2) are already securing major partnerships (e.g., Chai-Lilly), proving that the 'front end' of AI-driven dr…

AI reasoning models combined with fully robotic 'autonomous labs' can run experimental cycles 24/7, share data instantly across 100+ parallel AI scientists, and shift R&D spend from overhea…

Lab automation has been stuck at 'subway' levels (low mix, high volume) but AI enables 'Waymo-level' autonomy — handling the thousand-device integration and liquid-handling edge cases that…

The Department of Energy's Project Genesis — backed by the White House OSTP — is installing Ginkgo's autonomous lab systems at national labs to accelerate strategic science (materials, ener…

China now publishes more scientific papers and captures 40%+ of biotech licensing deals (up from <5% three years ago) due to more experimentalists at lower cost; the US must adopt AI-driven…

Drug development costs have risen for 25 years because the dominant expenses (scientists, lab space, overhead) are labor-intensive and don't scale; only full automation of experimental work…

GLP-1 agonists represent a shift from treating disease to enhancing healthy human traits (weight, appetite control), creating a consumer biotech market potentially worth $50T+ if lifespan-e…

Weekly blood-based molecular profiling (as pioneered by Bryan Johnson) will replace wearables as the primary health data layer, allowing individuals to test interventions and measure aging…

Ginkgo's new cloud lab service (Igen) offers remote robotic experiments starting at $39 with data-only return, potentially enabling millions of 'citizen scientists' to run real experiments…